Berobenatide
VESPER-3
Pfizer · Phase 2 · Completed · Enrollment 268
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| MET097 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- MET097: endpoint not reported
- Placebo: endpoint not reported